(4-Methoxyphenyl)(4-piperidyl)methanone hydrochloride, 95.0%, 25g

tert-Butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolidine-1-carboxylate, 95.0%, 500mg

GC capillary column ROTI®Cap-1 MS, 60 m, 0.25 mm, 0.25 µm, 1 Piece(s)

Fmoc-Ala-Ala-OH, 98.0%, 5g

(S)-Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-methylbutanoate hydrochloride, 95.0%, 100g

6-Fluoro-2-methyl-3-(methylthio)pyridine, 95+%, 5g

1-(2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperidine, 95.0%, 5g

(S)-2-Isopropylmorpholine, 97%, 250mg

(4aR,7aS)-Octahydrocyclopenta[b][1,4]oxazine hydrochloride, 98%, 100mg

(2S)-3-N-Cbz-Amino-2-N-Fmoc-amino-propionic acid, 95.0%, 5g

2-Amino-6-ethoxybenzothiazole>97.0%(T)500g

4-(Di-p-tolyl-amino)-benzaldehyde, 95.0%, 25g

3-Chloro-4-methoxyphenylacetic Acid>97.0%(GC)1g